Bronchiolitis
Conditions
Keywords
Saline Solution, Hypertonic (3 %), Infant
Brief summary
Efficacy/Safety of 3% hypertonic saline inhalation (24H vs 72H) to treat acute bronchiolitis in infants.
Detailed description
In acute bronchiolitis in infants, 3% hypertonic saline nebulizations proved to be efficient, reducing the hospitalization length and clinical severity scores. Among the questions remaining, treatment length is still being discussed in the literature. The trial hypothesis is that the efficiency of a 24 hours treatment by 3% hypertonic saline is not inferior to a 72 hours treatment, in acute bronchiolitis in infants. The primary objective of the study is to compare the efficiency of a 24 hours treatment by 3 % hypertonic saline, versus a 72 hours treatment maximum, on clinical remission, judged by the Wang score measured 72 hours after starting treatment, in children younger than 12 month hospitalized for acute bronchiolitis.
Interventions
DRUG3 % hypertonic saline up to 72H
Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
DRUG3 % hypertonic saline up to 24H
* Treatment by inhalation of 3 % hypertonic saline, up to 24H. * followed by 48h of placebo : isotonic saline inhalation. Placebo control group.
Sponsors
AGIR à Dom
University Hospital, Grenoble
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
1 Minutes to 12 Months
Healthy volunteers
No
Inclusion criteria
* 1st or 2nd episode of acute bronchiolitis, defined by respiratory symptoms episode with initial rhinitis, then cough, then one of the following symptoms : wheezing, crackling, respiratory distress * Winter epidemic period from November, the 15th, to March the 15th * Age \< 12 months * Admission Wang score included between 4 and 8 * Infant hospitalized for gravity clinical criteria of severity * Nebulized 3 % hypertonic saline treatment since less than 24 hours * Infant with social security card coverage * Free consent of at least one of the parental authority holder
Exclusion criteria
* Pulmonary, cardiac or neurologic chronic underlying disease * Prematurity \< 32 GW * Asthma (3rd episode or more) * Admission oxygen saturation level \< 85 %, Wang score ≥ 9
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wang score after 72 hours of treatment | 72 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine percentage of patient needing transfer to the PICU or use of mechanical ventilation | From Day 1 to end of the hospitalisation, assessed at EOS (End of study for the patient, meaning discharge from hospital) | Percentage of patient needing transfer to the PICU or use of mechanical ventilation |
| To assess average time of Oxygen therapy | From Day 1 to end of the hospitalisation, assessed at EOS (End of study for the patient, meaning discharge from hospital) | average time of Oxygen therapy in days |
| Recovery time | From Day 1 to end of the hospitalisation within 2 weeks, assessed at EOS (End of study for the patient, meaning discharge from hospital) | Secondary outcomes will be assessed during the hospital stay for acute bronchiolitis, from inclusion date until day of hospital discharge, within 2 weeks. |
| To determine variation of Wang score during hospitalisation | measured at Day 1, 2, 3, 4 and day of discharge. | Wang score, |
| To determine percentage of patient with Adverse Event | From Day 1 to end of the hospitalisation, assessed at EOS (End of study for the patient, meaning discharge from hospital) | percentage of patient with Adverse Event |
| To assess average time of Tube feeding | From Day 1 to end of the hospitalisation, assessed at EOS (End of study for the patient, meaning discharge from hospital) | average time of Tube feeding in days. |
Countries
France
Outcome results
None listed